IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS.
Hartwig, Jelka, Sotzny, Franziska, Bauer, Sandra et al. · Brain, behavior, & immunity - health · 2020 · DOI
Quick Summary
This study examined a specific immune problem in some ME/CFS patients: abnormal antibodies that interfere with a receptor protein called β2 adrenergic receptor, which helps regulate immune response and stress recovery. Researchers found that immune cells (antibodies) from healthy people could activate this receptor and boost immune regulation, but antibodies from ME/CFS patients with elevated levels of these specific autoantibodies could not. This dysfunction in the immune system may help explain why ME/CFS patients experience persistent fatigue and immune dysregulation.
Why It Matters
This research identifies a potential biological mechanism underlying immune dysregulation in ME/CFS—dysfunction in β2 adrenergic signaling that normally suppresses inflammatory responses and promotes immune recovery. Understanding this mechanism could inform the development of targeted therapies to restore β2 AdR function and provide a biological basis for symptoms like impaired stress response and persistent inflammation in affected patients.
Observed Findings
IgGs from healthy controls stimulated β-arrestin recruitment and cAMP production in β2 AdR reporter cells, while IgGs from AAB_high ME/CFS patients had no significant effect
Healthy control IgGs inhibited LPS-induced TNFα production and stimulated IL-10 production in monocytes; AAB_high patient IgGs showed no significant effect
Healthy control IgGs enhanced T cell proliferation in response to anti-CD3/CD28 stimulation; AAB_high IgGs were ineffective
IgGs from CFS AAB_norm patients showed intermediate effects between healthy controls and AAB_high patients across all measured parameters
IgG can directly activate β2 adrenergic receptor signaling in healthy individuals, contributing to anti-inflammatory immune regulation
In ME/CFS patients with elevated β2 AdR autoantibodies, this IgG-mediated receptor activation is impaired, potentially explaining dysregulated immune responses and abnormal inflammatory patterns
Dysregulation of β2 AdR signaling by autoantibodies may represent a mechanistic basis for multiple ME/CFS symptoms including fatigue, immune dysfunction, and abnormal stress responses
Remaining Questions
Does β2 AdR autoantibody presence correlate with symptom severity, disease duration, or treatment response in ME/CFS patients?
What This Study Does Not Prove
This study does not establish that β2 AdR autoantibodies cause ME/CFS or that all ME/CFS patients have this abnormality (only a subset showed elevated antibodies). The in vitro findings may not fully translate to clinical outcomes in patients, and correlation between autoantibody presence and symptom severity or disease progression was not established. Causality cannot be inferred from this mechanistic study alone.